TY - JOUR
T1 - Rationale for eliminating the hormone-free interval in modern oral contraceptives
AU - London, Andrew
AU - Jensen, Jeffrey T.
N1 - Funding Information:
Medical writing assistance was provided by MedVal Scientific Information Services (Skillman, NJ, USA) and was funded by Teva Branded Pharmaceutical Products R&D (Frazer, PA, USA). Teva provided a full review of the article. A.L. has served on an advisory board for Shionogi; has been a paid speaker for Shionogi, Noven, and Pfizer; and is the primary investigator in two contraceptive trials for Bayer Pharmaceuticals. J.T.J. has served on advisory boards for Abbvie, Agile, Bayer Healthcare, ContraMed, Evofem, HRA Pharma, Merck, MicroChips, and Teva; and has received research funding from Agile , Abbvie , Bayer Healthcare , ContraMed , Evofem , HRA Pharma , and Merck . These potential conflicts of interest have been reported to and are managed by Oregon Health and Science University.
Publisher Copyright:
© 2016 International Federation of Gynecology and Obstetrics.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Background Although most low-dose combined oral contraceptives (COCs) include 7-day hormone-free intervals (HFIs), these COCs could incompletely suppress ovarian activity. Objectives To review the impact of HFIs on ovarian suppression and tolerability, and evaluate the utility of COCs without traditional 7-day HFIs. Search strategy PubMed was searched for clinical studies published in English between January 1980 and April 2015 on the impact of HFIs and HFI modifications in COCs. Selection criteria Articles assessing contraceptive efficacy or tolerability as the primary focus were included. Data collection and analysis Abstracts of 319 articles were screened. Results Analysis of the 161 articles selected revealed that suppression of ovarian activity with low-dose COCs with 7-day HFIs is suboptimal. Loss of ovarian suppression during 7-day HFIs is commonly associated with follicular development, and most dominant follicles appear during this period. By contrast, increased ovarian suppression was noted in regimens that shortened or eliminated the HFI, or that substituted low-dose ethinyl estradiol for the HFI. Conclusions Extended regimens with modified HFIs may provide greater ovarian suppression with the potential for increased contraceptive effectiveness. Additional research is needed to evaluate whether COC regimens that include 10 μg ethinyl estradiol instead of an HFI may improve tolerability.
AB - Background Although most low-dose combined oral contraceptives (COCs) include 7-day hormone-free intervals (HFIs), these COCs could incompletely suppress ovarian activity. Objectives To review the impact of HFIs on ovarian suppression and tolerability, and evaluate the utility of COCs without traditional 7-day HFIs. Search strategy PubMed was searched for clinical studies published in English between January 1980 and April 2015 on the impact of HFIs and HFI modifications in COCs. Selection criteria Articles assessing contraceptive efficacy or tolerability as the primary focus were included. Data collection and analysis Abstracts of 319 articles were screened. Results Analysis of the 161 articles selected revealed that suppression of ovarian activity with low-dose COCs with 7-day HFIs is suboptimal. Loss of ovarian suppression during 7-day HFIs is commonly associated with follicular development, and most dominant follicles appear during this period. By contrast, increased ovarian suppression was noted in regimens that shortened or eliminated the HFI, or that substituted low-dose ethinyl estradiol for the HFI. Conclusions Extended regimens with modified HFIs may provide greater ovarian suppression with the potential for increased contraceptive effectiveness. Additional research is needed to evaluate whether COC regimens that include 10 μg ethinyl estradiol instead of an HFI may improve tolerability.
KW - Combined oral contraceptives
KW - Extended regimen
KW - Hormonal contraception
KW - Hormone-free interval
KW - Menstrual suppression
KW - Unscheduled bleeding
KW - Withdrawal bleeding
UR - http://www.scopus.com/inward/record.url?scp=84975246471&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975246471&partnerID=8YFLogxK
U2 - 10.1016/j.ijgo.2015.10.028
DO - 10.1016/j.ijgo.2015.10.028
M3 - Review article
C2 - 27067074
AN - SCOPUS:84975246471
SN - 0020-7292
VL - 134
SP - 8
EP - 12
JO - International Journal of Gynecology and Obstetrics
JF - International Journal of Gynecology and Obstetrics
IS - 1
ER -